Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07706777
Recruiting Phase 2

Clinical Study of HRS-2129 for Acute Gouty Arthritis

NCT07706777 · tracked via the Priya Life Science China tracker
Sponsor
Shandong Suncadia Medicine Co., Ltd
Phase
Phase 2
Started
2026-08-19
Last updated
2026-09-03

Condition(s) studied

Acute Gouty Arthritis

Investigational drug(s) / intervention(s)

HRS-2129 Tablet →HRS-2129 Tablet →Placebo

HRS-2129 Tablet: HRS-2129 Tablet; high dose

HRS-2129 Tablet: HRS-2129 Tablet; low dose

Placebo: HRS-2129 Tablet Placebo

Study summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. Subjects requiring Acute gouty arthritis 3. Target joint VAS pain score ≥ 50 mm (screening) Exclusion Criteria: 1. Subjects with a history of severe allergies 2. Subjects with nervous system disease 3. Subjects with a history of mental illness 4. Subjects with abnormal liver and renal function 5. Subjects with poorly controlled hypertensive 6. QTc：\>450ms（male），\>470ms（female） 7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 8. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Primary outcome measure(s)

  • Change from baseline inVisual Analogous Scale pain score at 24 hours post first dose — from ICF signing date to 24 hours after first dose
    VAS，Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack，it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain)

Trial sites (2)

FacilityCityRegionStatus
The Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong Recruiting
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu Recruiting

More Shandong Suncadia Medicine Co., Ltd. trials in China

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors Recruiting
Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study Starting soon
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events Starting soon
A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 Starting soon

Other trials for the same condition

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis Recruiting
A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07706777 on ClinicalTrials.gov ↗ ← All trials in China